price month
 close
initi coverag outperform
product launch reinvest drive growth share
gain initi coverag outperform rate target price
recent spun parent novarti alcon market leader eye care
devic vision care reinvest initi past three
year part novarti alcon posit deliv improv growth
margin key alcon invest case opportun
increas revenu growth margin expand market share
leadership posit cataract retin surgeri contact lens
disrupt trifoc len win outsid us first kind
us alcon lost share last year advanc tech
intraocular len at-iol segment cataract market howev
panoptix trifoc len regain share europ believ
experi us could signific fda-
approv trifoc iol expect panoptix above-
market share growth captur share
revenu growth estim contact lens assum
share gain given alc signific us gain
far premium multifoc daili project could conserv
margin improv driven leverag stand-up cost relat
spin oper effici improv mix new product
valuat target price deriv ev/ebitda
project next month ebitda one year today bil
multipl roughli line stock current trade multipl
project ntm ebitda risk delay key product failur progress
ltp object potenti litig regulatory/safety-rel issu
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
alcon medic devic compani focus eye care alcon
develop manufactur distribut full suit eye care
product within two key busi surgic vision
one-year valuat scenario base
ev/ebitda multipl ntm ebitda bil
forward scenario base high-growth
segment grow core growth segment grow
one-year valuat grey scenario base
ev/ebitda multipl grey ntm ebitda bil
forward grey scenario base high-growth
segment grow core growth segment grow
 close
tabl content
drive reacceler alcon ophthalm surgeri busi
overview major busi line
spin-off capit structur
financi statement project
figur launch panoptix drive at-iol market share recaptur
 launch panoptix
signific catalyst
growth drive
recaptur
figur daili contact len acceler growth market share
higher revenu mix
increment
market share
figur analysi holt oper margin expans spin
year suggest alc estim reason conserv
bp
roughli
line manag
compar median
margin expans
almost bp
compar
note detail alc holt pleas see alcon alc holt eye novarti spin-off
figur med-tech spin solid histori out-performance
spin
outperform
market averag
first
year
two- three-year
 oper margin chang bp holt oper marginmedianalc op mgn expansionspinperf rel charl martineau pm univers toronto
initi coverag alcon inc alc outperform target price
spun novarti april alcon offer exposur grow global surgic vision
care market leadership posit cataract retin surgeri contact lens
consum eye care expect see valu creation driven share recaptur
re-acceler growth cataract premium iol market driven disrupt
panoptix trifoc len share gain improv growth contact lens driven
increas penetr daili dispos segment market margin
improv driven leverag standup cost relat spin oper effici
improv mix new product
first-to-market us disrupt advanc technolog len cataract
alcon track first us disrupt trifoc iol inter-ocular len
expect help compani re-captur market share
repres above-market revenu share gain
past year compani cede share advanc tech intraocular len
at-iol segment cataract market see gain europ follow
launch acrysof panoptix trifoc len believ experi us could
even signific given fda-approv trifoc iol least
next year bausch competitor current develop similar product
us
expans daili contact lens drive growth
revenu growth estim contact lens assum
share gain given alc signific us share gain far
premium multifoc daili driven daili multifoc project could
turn conserv upcom launch daili us
mark alcon entri fastest-grow mid-rang price segment market
annual margin improv acceler compani
well posit deliv solid near-term margin improv driven leverag
stand-up cost oper effici net posit product mix driven at-iol
growth posit margin howev posit like off-set partli
growth daili dispos contact slight neg margin effect alcon
complet construct new manufactur facil subsequ
ramp optim product believ improv absorpt
capac util improv margin beyond
retin surgeri dri increas intern at-iol penetr
addit two key growth driver pathway improv margin see
addit complementari posit valu driver help alcon reach
intermedi long-term oper object
vitreoretin surgeri compani market share
opportun drive adopt lower-gaug instrument use
instrument improv effici reduc time growth retin diseas
also unfortun tie rise diabet improv capabl
diagnosi drive volum higher
dri improv diagnosi patient awar educ
potenti drive greater adopt alcon market-lead systan dri
eye product target bil opportun ocular
at-iol penetr remain less half us
creat opportun growth focus key market region like
japan latin america emea rest asia alcon expect rais
combin row penetr line us would repres mil
valuat target price deriv ev/ebitda project next
month ebitda one year today bil multipl roughli line
stock current trade multipl project ntm ebitda
potenti delay failur product approv launch timelin
clinic timelin reimburs product launch includ
panoptix trifoc len daili dispos mainstream sihi
len well non-diffract presbyopia correct iol failur execut
pipelin opportun expand geograph new emerg market may result
compani fail achiev financi goal product becom obsolet
custom switch competit product could materi
impact alc revenu profit
slower expect uptak commerci adopt pipelin
product slower adopt traction key pipelin product especi
panoptix could materi advers impact compani
revenu market share assumpt well price perform sharehold
new fda quality-rel issu extend remedi fda warn
letter warn letter could result signific modif compani
oper potenti recal inabl obtain futur pre-market approv
remov current product market result addit remedi cost
potenti delay disrupt product approv avail
alcon
increas diabetes-rel diseas
invest manufactur new product drive surgic growth
compani began reinvest manufactur seen
increas benefit past year result see two key driver
improv surgic sale growth next year launch panoptix
continu execut differenti product global increas share
mix driven alcon differenti vitreoretin equip instrument platform
constel two detail analysi slightli focus first given
potenti model growth share gain mix panoptix launch
expect begin said term vitreoretin see shift
smaller gaug instrument import driver effici mix
retina space strong
albeit unfortun growth driver surgeri growth area
acrysof panoptix disrupt trifoc iol make debut
advanc technolog iol at-iol area growth within rel
matur intraocular len market year howev growth categori
held back shortcom patient satisfact variabl outcom
new iter technolog innov anticip high hope
bausch accommod crytalen amo/jnj tecni symfoni none broken
away group standout reproduc result discuss what special
panoptix challeng address patient need cataract surgeri
detail later report what differ panoptix len
trifoc gener garner substanti posit respons europ
len avail importantli panoptix track first trifoc iol reach
 next year could enjoy competit advantag trifoc
 two year context at-iol market current bil
repres total iol market dollar term unit due
underinvest fall behind multifoc presbyopia-correct pc iol
segment alcon share at-iol deterior around around
today estim set stage substanti share recaptur
launch differenti arguabl disrupt product
estim panoptix drive least market share recaptur
project implant sale driven larg growth iol assum
compani global busi continu reacceler modestli
significantli beyond driven launch panoptix given
len highli differenti seen favor traction europ expect growth
uptak quit posit next year help alcon recaptur least
half share at-iol market compani lost past
year summar pace share gain reflect estim
estim also includ detail model later report
charl martineau pm univers toronto figur market share recaptur at-iol market driven launch panoptix
improv contact len sale growth key driver alc
manag highlight upcom daili contact len launch key
element compani long-term growth plan daili lens power growth driver
contact len manufactur annual sale per patient daili higher
frequent replac frp lens alc daili single-us dispos
market sinc focus premium end daili len market
total contact len market alc first entri
mid-rang mainstream segment market fastest grow segment
estim contact len market bil reflect unit penetr
daili lens account around sale bil
estim alc contact len busi drive share
expect launch drive addit penetr daili market
compani partial off-set cannib sale compani exist
daili product import note assum convers patient
daili take time given patient gener switch contact len
system often promot trial take time impact sale share
result growth project cumul market share estim
illustr assum increment market share alcon
accru
figur acceler growth contact len share driven launch
panoptix presbyopia correct len provid vision distanc intermedi
arm length near trifoc len correct problem intermedi vision
multifoc lens address distanc near focu biggest benefit trifoc
intraocular lens possibl see clearli distanc without glass
remain earli data limit panoptix also shown promis result
intermedi vision halo effect compar multifoc lens market
well compar trifoc current avail europ one signific
challeng wider adopt pc-iol patient satisfact
near intermedi vision patient complaint halo low light night
clinician reluct recommend premium lens risk patient
satisfact therefor see innov differenti behind trifoc
initi evid panoptix improv key area signific
figur improv perform near intermedi distanc vision
compani acrysof iq panoptix trifoc iol launch select outsid
market ce mark launch nordic alcon experienc
increas sale share captur panoptix sale
increas canada period panoptix launch
plan late compani expect len increas
compani abil take market share expect drive share
mix also expect panoptix trifoc price premium multifoc lens
expens monofoc
figur panoptix promis track record growth eu canada
panoptix compet market leader carl zeiss trifoc len lisa oversea
market well trifoc lens finevis panoptix first trifoc len
 bausch health present work trifoc call envista
figur current avail outsid trifoc manufactur
daili dispos sihi silicon hydrogel contact len intend compet
within mainstream sub-categori global daili dispos contact len market
fastest grow sub-categori daili dispos lens daili dispos
mainstream sihi lens price premium daili dispos sihi lens
compani offer daili len lower-ti daili dispos non-sihi
lens daili aquacomfort expect select launch
late global roll-out toward end go earli
round compani daili dispos portfolio next five year
compani expect overtak daili growth contribut
biggest growth driver daili segment context daili grown
compound-annual-growth-rate current share daili sihi categori compani
bake cannib daili launch
sihi alc enter crowd field major competitor alreadi offer
silicon hydrogel lens howev manag still see opportun take share
figur target fastest grow categori dd lens
compani describ daili lubrici
high water content howev driver behind featur lie len proprietari
gel surfac technolog alcon encapsul daili line proprietari
layer hydrat gel make lens comfort sustain hydrat
carri key differenti featur mainstream segment
silicon hydrogel lens fastest grow segment contact len market --
trade-up tradit hydrogel silicon hydrogel len gener addit
premium within daili dispos silicon hydrogel len market mainstream
sub-seg grow faster premium lower tier non-sihi
segment silicon hydrogel materi signific allow oxygen pass
len cornea regular hydrogel contact help prevent red eye
corneal swell blur vision eye discomfort silicon hydrogel contact lens
account share
at-iol implant compani focus drive growth
increas market share at-iol grow excess
compar unit growth monofoc at-iol repres
ww market unit constitut ww market revenu compar
unit share monofoc market revenu remain
signific opportun increas penetr well grow outsid
 penetr north american level compani
estim repres market opportun mil
panoptix launch panoptix late expect
key stock driver compani acrysof iq panoptix trifoc iol launch
select outsid market panoptix launch
 compani expect panoptix increas compani abil take
share expect drive share mix analysi
estim panoptix drive least market share recaptur
context panoptix presbyopia correct len provid vision
distanc intermedi arm length near
vitreoretin surgeri compani vitreoretin surgeri busi anoth
growth driver surgic market growth led age popul
well rise preval diabet drive retin diseas
growth addit increas access retin specialist also consid
growth driver compani instal base share vitrectomi
daili contact lens compani drive growth focus
daili grow daili famili product capit
shift daili dispos lens revenu daili lens actual
daili wearer rang impli signific long-term
systan complet systan complet key growth driver ocular
compani focus direct-to-consum campaign undiagnos dri
eye patient well patient self-diagnos choos unsuit
product dri eye treatment compani estim global market
opportun dri eye bil
len intend compet within fastest grow mainstream sub-categori
global daili dispos contact len market round daili
dispos portfolio launch schedul late
next five year compani expect overtak daili
growth contribut biggest growth driver daili
margin expans on-going margin expans key stock driver also compani
well-posit deliv solid near-term margin improv driven leverag
stand-up cost oper effici net posit product mix driven at-iol
growth posit margin partial off-set growth daili dispos contact modest
neg margin estim margin improv bp
ramp beyond
earn may compani report first quarterli earn post
spin may expect updat surgic vision busi
novarti report result april report full quarter result
alcon discontinu oper alcon sale report novarti
bil flat vs constant currenc basi oper margin
new product launch on-going highlight new product alcon expect
launch expect key growth driver
trifoc major new iol platform accommod non-diffract presbyopia correct iol clareon autonom us gener cataract vitreoretin technolog charl martineau pm univers toronto
overview major busi line
alc organ two main segment surgic vision surgic
segment compris implant consum equipment/oth vision
segment compris contact len ocular health figur provid
overview major busi line size geograph mix growth profil well
primari competitor key product
figur sale major busi line geographi
sale geographi
figur overview major busi line surgic
salesvis cagrcomp productsimplant implant product address cataract vitreoretin condit refract error forwardcarl zeiss meditec bausch health jnjacrysof iol ultrasert pre-load iol clareom autonom pre-load iol consum consum product support ophthalm surgic procedur viscoelast product surgic solut incision instrument alcon dedic forwardcarl zeiss meditec bausch health jnjcustom pak surgic preocedur pack miv platformequip surgic equip address cataract vitreoretin condit refract error forwardcarl zeiss meditec bausch health jnjcenturion vision system cataract remov constel vision system vitreoretin surgeri wavelight refract laser use lasik charl martineau pm univers toronto figur overview major busi line vision
cagrcomp productscontact lensdaili dispos reusabl color-enhanc contact forwardjnj bausch health coodaili water gradient lens daili comfort optix monthli reusabl lens aur optix color cosmet lens freshlook cosmet lensesocular healthover-the-count product dri eye contact len care ocular allergi well ocular vitamin red forwardjnj bausch health coosystan famili dri eye product clear clean disinfect solut opti-fre famili multi-purpos solut rewet dropsvis charl martineau pm univers toronto
target price reflect new product launch share gain
iol contact lens
target price deriv ev/ebitda project next month
ebitda one year today bil multipl roughli line stock
current trade multipl project ntm ebitda slight premium
comp group reflect alc growth driver margin expans potenti
rel peer outperform rate invest thesi driven share
recaptur re-acceler growth cataract premium iol market driven
disrupt panoptix trifoc len share gain improv growth contact
lens driven increas penetr daili dispos segment market
margin improv driven leverag standup cost relat spin
oper effici improv mix new product
share price april
ep cagr shown alc period post spin
one-year valuat scenario base
ev/ebitda multipl ntm ebitda bil one-year
forward scenario base high-growth segment grow
core growth segment grow
grey one-year valuat grey scenario base
ev/ebitda multipl grey ntm ebitda bil one-year
forward grey scenario base high-growth segment grow
core growth segment grow
risk target price rate follow
potenti delay failur product approv launch timelin
clinic timelin reimburs unfavor result unforeseen
circumst relat compani clinic program could result delay
failur regulatori approv new product plan modif indic
expans exist product product launch includ
panoptix trifoc len daili dispos mainstream sihi len
well non-diffract presbyopia correct iol beyond compani
expect launch four major new iol platform next-gen cataract vitreoretin
technolog platform well accommod contact lens potenti
advers event challeng materi affect oper cost potenti
sale growth compani
slower expect uptak commerci adopt pipelin
product slower adopt traction key pipelin product especi
panoptix could materi advers impact compani
revenu market share assumpt well price perform sharehold
return optometrist eye care profession may slow adopt compani
product surgic vision side due lack experi use
alc product prefer competitor product cheaper altern
competitor especi emerg market
new fda quality-rel issu extend remedi fda warn
letter alc product regul fda non-compliance regulatori
requir could result potenti warn letter warn letter may lead
signific modif compani oper potenti recal inabl
obtain futur pre-market approv remov current product
market remedi warn letter consist comprehens plan
correct action could drawn materi advers effect
compani term addit remedi cost potenti delay disrupt
product approv avail compani current
outstand warn letter fda
failur show progress toward long-term alc long-term
financi goal present investor analyst day lay rang
long-term object relat sale growth oper margin free cash flow
compani unabl achiev target could materi advers
impact price perform sharehold return
alcon report revenu two major categori surgic vision
discuss detail almost compani revenu gener outsid
 compani hold global market share ophthalm surgic market
global market share vision care market
figur alc revenu segment
figur alc revenu geographi
bil sale compound-annual-growth-rate
line ophthalm surgic devic includ
implant consum equip use surgic procedur address
cataract vitreoretin condit eye diseas affect retina vitreou fluid
around refract error glaucoma compani market posit
figur surgic revenu segment
salesvis charl martineau pm univers toronto figur surgic segment detail summari
consum repres surgic sale bil consist product
support ophthalm surgic procedur cataract consum single-us
vitreoretin instrument consum refract consum well custom pak
person
configur request individu surgeon includ alcon single-us
product well third-parti item drape incision instrument
materi need perform particular type surgeri compani
bil consum busi deriv dedic product interfac
equip platform cassett pack patient interfac alcon offer
configur custom pak surgic procedur pack global use
compon compani hold posit
world-wide
iol artifici lens implant insid eye replac eye natur len
remov cataract surgeri cataract surgeri perform
ophthalmologist outpati basi either tradit use ultrasound energi
remov cloudi len laser-assist technolog phacoemulsif
surgeon make tini incis cornea use probe transmit
ultrasound wave break cataract suction fragment laser
procedur surgeon use laser make incis soften cataract
figur anatomi
implant account surgic revenu bil project grow
next five year brand implant includ acrysof famili
iol recent launch ultrasert clareon autonom pre-load iol deliveri
monofoc iol monofoc iol common type len use
cataract surgeri one focus distanc either set focu
close medium rang distanc vision patient often wear eyeglass
read close work get monofoc iol monofoc iol
spheric optic design mean front surfac uniformli curv
center len peripheri product includ acrysof iq monofoc
iol basic cataract surgeri well ultrasert pre-load iol deliveri
system use acrysof iq monofoc iol
multifoc iol multifoc iol provid distanc near focu
time contain ad magnif differ part len expand
patient rang vision see object clearli distanc without glass
contact lens multifoc iol use address presbyopia age-rel
farsighted multifoc iol premium lens command
price premium spheric lens compani launch
multifoc acrysof restor offer launch acrysof iq
panoptix presbyopia- astigmatism-correct iol select market
europ canada outsid us
iol
correct astigmat
imperfect curvatur eye cornea len well nearsighted
farsighted toric lens align mark peripher part
len enabl surgeon adjust orient iol insid eye
optim astigmat correct toric iol also consid premium
lens compani launch acrysof iq toric len follow
acrysof iq restor toric iol address presbyopia
preexist astigmat time cataract surgeri
compani launch acrysof iq restor toric iol featur fewer
diffract step space apart smaller diffract region
accomod iol accommod iol premium intraocular lens
expand rang clear vision aspher design flexibl haptic
allow accommod iol move forward slightli look
near object increas focus power eye enough provid better
near vision convent monofoc len
pleas see review major market section report overview iol
implant compani focus drive growth increas market
share at-iol at-iol grow excess compar unit growth
monofoc said monofoc iol still repres major market
howev at-iol sale per patient repres premium compar
monofoc at-iol repres world-wide market unit constitut
world-wide market revenu compar unit share monofoc
market revenu alcon market leader world-wide iol segment
share follow bausch carl zeiss north american
market penetr at-iol compar outsid
remain signific opportun increas penetr well grow
outsid penetr north american level compani identifi
presbyopia-correct iol brand pc-iol -- panoptix key growth driver
implant context compani acrysof iq panoptix trifoc iol launch
select outsid market acrysof iq panoptix toric len
launch select intern market nordic alcon experienc
increas sale share captur panoptix sale
increas canada period product expect
launch compani expect panoptix increas compani abil take
share context panoptix presbyopia correct len provid vision
distanc intermedi near limit level halo glare compar
equip account surgic sale bil project grow
compound-annual-growth-rate next year major alcon equip revenu
gener centurion cataract phacoemulsif consol constel
vitrectomi consol also drive substanti portion compani
consum implant
centurion alcon market-lead phacoemulsif platform hold
market share instal base global follow bausch
centurion compani flagship phacoemulsif system sinc
addit custom pack use conjunct system
procedur centurion system often use remov
implant intraocular len iol therefor key driver
constel compani vitrectomi platform share follow
bausch dorc share world-wide base instal base unit
perform cataract vitrectomi procedur constel
vision system continu drive compani market share global
premium segment vitrectomi pack addit compani also offer full
line vitreoretin product includ procedur pack laser hand-held
microsurg instrument well grieshab miv line
dispos retin surgeri instrument focu advanc
compani portfolio smaller gaug instrument higher cut speed
vitrectomi probe smaller gaug instrument result smaller incis
decreas risk infect well elimin need incis
sutur term high cut speed vitrectomi probe faster cut rate
better help prevent retin damag gel remov
wavelight alcon market-lead femtosecond refract laser system use
lasik correct procedur compani hold market share
refract laser follow carl zeiss addit wavelight
compani contoura vision system enabl surgeon perform topographi
guid procedur accur method measur eye structur
person patient lasik procedur refract surgeri sale driven
capit sale leas equip dispos patient interfac use
laser correct procedur technolog fee diagnost devic
necessari plan refract procedur
lensx use creat incis cornea creat capsulorhexi techniqu
use remov capsul len eye cataract surgeri
system effect replac phacoemulsif approach laser-driven
approach nativ len fragment remov
verion compani also manufactur verion refer unit verion
digit marker togeth form surgic plan imag guidanc
technolog well system intra-op measur
improv placement precis implant iol cataract surgeri
post-op aid measur outcom analysi
glaucoma surgeri compani offer glaucoma
filtrat devic use part trabeculectomi procedur lower
intraocular pressur insid eye patient glaucoma
compani voluntarili withdrew
cypass
micro-st market cypass design reduc intraocular pressur
treatment glaucoma cypass micro-st approv fda
juli use conjunct cataract surgeri adult patient
mild-to-moder primari open-angl glaucoma base result
two-year compass studi demonstr statist signific
reduct intraocular pressur two year post-surgeri subject implant
cypass micro-st time cataract surgeri compar
subject undergo cataract surgeri alon two year post-surgeri
littl differ endotheli cell loss cypass micro-st
cataract surgery-onli group result consist peer-review
literatur benchmark cataract-rel endotheli cell cell line interior
surfac blood vessel lymphat vessel form interfac
circul blood lymph lumen rest vessel wall loss
compass-xt studi design collect safeti data subject
particip compass studi addit three year analysi
complet data set five year post-surgeri five year cypass
compar group underw cataract surgeri alon result
compani withdrew product market august
pleas see review major market section report overview
ww share follow bausch
femtosecond laser use cataract surgeri
ww share follow bausch
oper speed cut per minut
cpm help reduc traction caus
iatrogen tear post-op complic
ultra-high definit display
offer improv depth percept
ww share follow carl
consist excim laser reshap
cornea femtosecond laser creat
corneal flap deliv laser refract therapi
lasik surgeri
topography-guid lasik treatment provid
surgeon abil perform
person laser procedur patient
nearsighted nearsighted
use part trabeculectomi procedur
devic implant scleral flap
enhanc outflow aqueou humor reduc
intraocular pressur patient open-angl
compani identifi vitreoretin space near-term growth driver
promot smaller incis surgeri safer micro-gaug vitrectomi instrument like
miv market growth led age popul well rise preval
diabet drive retin diseas growth diseas comorbid
link preval diabet addit increas access retin specialist
also consid growth driver context retin specialist
per million peopl compar china emerg market continu grow
rise number eye care profession train improv access
technolog factor drive demand compani vitreoretin product
bil sale compound-annual-growth-rate
alcon vision busi consist extens portfolio contact len ocular
health product compani market posit global vision care market
contact len vision consist primarili daili dispos reusabl
color-enhanc contact lens ocular health vision includ
product over-the-count product dri eye contact len care ocular
allergi well ocular vitamin red reliev
figur vision revenu segment
contact lens repres vision sale consist varieti daili
dispos reusabl color-enhanc contact lens brand includ daili
daili aquacomfort daili optix monthli replac product
line compani hold posit world-wide contact len market behind
compet premium price segment market use improv
function design consum conveni maintain price power
daili lens daili contact lens design one-tim use
dispos everi day product includ daili aquacomfort
daili also offer multifoc design address
presbyopia well captur consum tradit drop
contact lens
reusabl lens reusabl contact lens design period use
 monthli weekli etc requir daili clean mainten
hydrogel contact lens monofoc astigmatism-correct multifoc
option compani optix lens outfit hydraglyd
technolog longer last len surfac wettabl well smartshield
technolog help len resist lipid deposit deliv wettabl
color-enhanc lens worn cosmet reason freshlook
famili color contact lens part optix color monthli
water gradient contact len market also offer
multifoc design address presbyopia market premium dd sihi
ideal patient tri dispos two-week replac
lens past releas blink-activ moistur throughout day
avail astigmat presbyopia also low-tier dd non-sihi
agent design attract len surfac moistur retain hydrat
smartshield technolog ultra-thin protect shield help lens resist
lipid deposit deliv wettabl avail weekli monthli
multifoc toric lens
color lens silicon hydrogel materi smartshield technolog
avail color monthli lens
cosmet contact lens worn even vision correct
contact lens compani drive growth focus daili grow
daili famili product specif compani focus capit
shift daili dispos lens primari market growth driver
revenu daili lens actual daili wearer rang
impli signific long-term trade-up opportun shift frequent replac
product frp daili lens gener revenu per patient alcon
market leader daili market share ahead share
daili compani estim daili market bil sale potenti
compani also plan launch new line contact
daili dispos sihi silicon hydrogel contact len
intend compet within mainstream sub-categori global daili dispos
contact len market silicon hydrogel lens fastest grow segment
contact len market trade-up tradit hydrogel silicon hydrogel
gener addit premium
addit compani also expand presbyopia age-rel farsighted
multifoc offer increas consum awar campaign focus
len comfort qualiti age eye get dryer presbyopia set
larg major presbyop opt read glass alcon aim chang
focus resourc consum educ campaign increas awar
alcon daili multifoc lens allow daili wearer see clearli
distanc distant intermedi near vision context sale alcon daili
multifoc lens grown multifoc market
grow faster toric sphere len market daili multifoc lens
launch
ocular health repres remain vision sale consist
over-the-count product dri eye contact len care ocular allergi well ocular
vitamin red reliev relat symptom red eye brand
compani ocular health busi includ systan famili artifici tear relat
dri eye product opti-fre multi-purpos disinfect solut clear line
hydrogen peroxid disinfect solut compani world-wide market leader
ocular
dri dri eye condit occur eye natur tear film
disturb insuffici lead discomfort potenti seriou chronic
vision deterior loss disord symptom address
artifici tear product brand includ systan famili artifici tear
dri eye product systan portfolio includ product daili
nighttim relief well product discomfort associ contact len
wear compani market posit dri eye
contact len contact len care clc product import reusabl
lens help reduc risk infect irrit associ contact
len use also help maintain visual acuiti increas comfort
wear reusabl contact lens remov contamin surfac
contact len addit len rewet drop also use rehydr
len wear clear away surfac materi product includ
opti-fre famili multi-purpos disinfect contact len care solut
clear famili hydrogen peroxid contact len care solut aosept
outsid compani market posit clc market
ocular vitamin ocular vitamin typic over-the-count dietari
supplement formul support eye health alcon key brand includ icap
vitalux vitamin mainten gener ocular health
allergi product compani also offer ocular health product
antihistamin combin antihistamin red reliev
address allerg conjunct occur conjunctiva eye
becom swollen inflam due reaction pollen dander mold
allergy-caus substanc result eye becom red itchi brand
includ genteal famili artifici tear tear natural famili
lubric eye drop well naphcon-a zaditor brand temporari
relief ocular itch due ocular allergi
ocular health compani identifi recent launch systan complet
key growth driver focus undiagnos dri eye patient mil patient well
patient self-diagnos choos unsuit product dri eye treatment
mil patient compani focus effort direct-to-consum
campaign drive awar consum demand context compani
systan complet eye drop receiv ce mark launch
canada eu offer fast hydrat long-last optim relief
variou type dri eye problem compani estim global market opportun
dri eye bil
alcon major player bil market expect grow
market compris surgic bil vision bil
expect discuss market detail
figur market segment
surgic market compris consum bil implant bil
equipment/oth bil bil surgic market alcon market leader
share follow carl zeiss ag bausch smaller
figur surgic market segment
consum market bil expect grow consum
consist cataract vitreoretin refract dispos instrument surgic solut
equip cassett patient interfac dispos item typic use
singl ophthalm surgic procedur cataract consum repres largest portion
follow vitreoretin refract consum market character
steadi procedur growth premium price support new equip
accompani consum compani hold posit world-wide
implant market gener bil sale ww expect grow
next year surgic implant includ monofoc advanc technolog
intraocular lens at-iol implant cataract surgeri market growth
driven shift monofoc iol unit growth at-iol
growth howev monofoc iol still repres major market
follow at-iol glaucoma devic at-iol repres
world-wide market unit constitut world-wide market revenu compar
unit share monofoc market revenu alcon market leader
world-wide iol segment share follow bausch health
zeiss north american market penetr at-iol
compar outsid remain signific opportun
increas penetr well grow outsid penetr north
american level compani estim repres market opportun
cataract surgeri involv monofoc iol gener fulli cover medic insur
provid govern reimburs program at-iol implant
may partial cover patient respons uncov portion
rang per eye iol tini artifici lens eye
replac eye natur len remov cataract surgeri patient
cataract len becom cloudi cataract surgeri remov cloudi len
replac clear iol improv vision iol made silicon acryl
monofoc iol one focus distanc set focu close medium
rang distanc vision multifoc iol decreas patient need glass
cataract surgeri consid premium lens contain ad magnif
differ part len expand rang vision enabl patient see object
clearli distanc without glass contact lens toric iol also premium
intraocular lens correct astigmat well nearsighted farsighted
differ power differ meridian len addit toric iol
also align mark peripher part len enabl surgeon
adjust orient iol insid eye optim astigmat correct
type at-iol includ aspher iol close match shape optic qualiti
eye natur len provid sharper vision accommod iol expand
rang clear vision aspher design flexibl haptic
figur ww iol market share bil
figur select iol type manufactur
equipment/oth segment surgic market bil expect grow
consist ophthalm equip use oper room well
associ technic clinic servic support train surgic equip
consist multi-us surgic consol laser diagnost instrument use across
variou procedur major condit eye surgic product
equip offer includ cataract vitreoretin disord refract error
myopia hyperopia astigmat glaucoma corneal diseas equip sale
gener cyclic year buy cycl alcon market share
equip world-wide phaco vitrectomi refract
phacoemulsif cataract occur natur len eye becom
cloudi primarili caus age protein len break
cataract treat surgic remov use phaco machin
cloud len insert artifici replac len phaco equip
compani share instal base world-wide basi term
penetr use phacoemulsif cataract remov less
penetr key emerg market compar
figur phaco market procedur penetr
percent total cataract procedur
vitrectomi vitreoretin surgeri involv specialist oper directli
retina membran tissu cover retina remov
vitreou humor gel-lik substanc eye treat diabet retinopathi
trauma tumor complic surgeri front eye pediatr
disord compani instal base share vitrectomi
machin follow bausch
note includ combin unit perform cataract vitrectomi procedur
treatment myopia
farsighted astigmat imperfect curvatur eye
cornea len laser refract surgeri lasik altern
eyeglass contact lens refract laser compani share
instal base follow carl zeiss
note includ excim femtosecond laser
cataract vitreoretin refract glaucoma surgeri mostli perform
outpati set refract laser correct at-iol often patient
co-pay portion third-parti coverag avail market growth driven growth
cataract vitreoretin procedur driven age popul increas access
care emerg market procedur per peopl vs
increas adopt advanc technolog like improv diagnost instrument
surgic option glaucoma manag increas world-wide preval
diabet eye diseas comorbid
vision market compris contact lens bil ocular health bil
expect grow next four year bil vision market
alcon hold global market posit behind vision care market
compris product design ocular care consum use primari custom
vision care product includ optometrist ecp tradit eye care profession
retail optic chain pharmaci well distributor resel directli
smaller retail ecp sell product end-us
figur vision market segment
contact len market bil project grow compound-annual-growth-rate
alcon market posit global tie behind
contact len market approxim penetr compar
outsid leav signific room expans
contact lens typic classifi modal daili reusabl frequent
replac product frp modal common split
daili daili design one-tim use dispos everi day
daili grow significantli faster hsd ldd compar reusabl
reusabl reusabl lens contact lens design period use
 weekli monthli etc requir daili clean mainten
lens also classifi design spheric multifoc toric design
common
spheric spheric contact lens len power throughout
entir optic part len correct myopia nearsighted hyperopia
farsighted major contact lens spheric design
address common visual acuiti need
toric toric lens differ power differ meridian len
correct astigmat well nearsighted farsighted
multifoc multifoc contact lens contain differ power zone near
far vision correct presbyopia well nearsighted farsighted
multifoc lens also correct astigmat
cosmet cosmet contact lens includ color contact design chang
intensifi eye color contact len prescript requir cosmet contact
even refract error need correct
toric multifoc lens consid premium lens command
price premium spheric lens due variou ad benefit grow faster
sphere
term growth profil multifoc fastest grow contact len design categori
repres sale unit growth respect
compani estim market current penetr multifoc see
signific room market expans toric grow mid-teen spheric len
growth msd hsd rang
figur daili contact len growth sale
figur daili contact len growth
overal market growth driven modal shift wearer base expans
geograph expans shift daili dispos lens reusabl lens result
increas sale per patient addit advanc specialti lens
combin increas demand toric multifoc cosmet lens also
help expand market patient wear contact lens age
estim current mil contact len wearer world-wide mil
contact len wearer drop varieti reason includ age howev
specialti lens allow user continu wear contact lens age addit
driver wearer base also includ increas incid myopia well
children enter contact len market earlier market growth also driven
acceler growth under-penetr intern market north america
western europ japan highli penetr market context
compani estim asian market penetr contact lens everi
percentag point increas result mil sale
contact len market face intens competit asian manufactur well
new entrant exist player challeng tradit distribut model
focus direct-to-consum e-commerc sale put pressur
tradit eye care profession ecp channel alcon signific presenc
 countri purchas contact lens current requir
prescript contact len consum act market primarili privat pay
patient pay contact lens pocket partial reimburs avail
countri optometrist visit portion contact len cost
contact lens made varieti materi includ
soft lens soft lens made gel-lik water-contain plastic call
hydrogel thin conform front surfac eye
silicon hydrogel lens silicon hydrogel lens advanc type
soft contact lens porou regular hydrogel lens allow
oxygen reach cornea silicon hydrogel contact lens
popular lens prescrib share
pmma lens pmma lens made transpar rigid plastic materi
call polymethyl methacryl pmma excel optic
transmit oxygen eye difficult adapt
ga permeabl lens ga permeabl lens rigid contact lens look
feel like pmma lens porou allow oxygen pass
also comfort pmma lens
hybrid lens hybrid contact lens rigid ga permeabl central zone
surround layer hydrogel silicon hydrogel materi howev
penetr low given lens difficult fit
expens replac soft silicon hydrogel lens
ocular health market bil project grow compound-annual-growth-rate
alcon market posit global market posit
dri eye contact len care compani key competitor ocular
allergan ocular health product includ product address dri eye contact len care
ocular allergi ocular vitamin red reliev
dri dri eye condit occur eye natur tear film
disturb insuffici effect patient rang intermitt
annoy discomfort seriou chronic vision-threaten disord market
growth driven increas awar treatment option well
age popul incid dri eye rise age addit
avail sophist diagnost tool greater varieti dri eye
product treatment also drive market estim
mil peopl global affect dri eye mil peopl
remain undiagnos mil undiagnos popul close
self-diagnos mil self-diagnos dri eye patient self-
diagnos patient choos unsuit product treatment repres
bil market opportun dri eye
figur mil dri patient self-
contact len proper care contact lens help reduc risk
infect irrit associ use reusabl contact lens contact
lens often get contamin cosmet greas bacteria soap hand lotion
atmospher pollut well protein contain natur tear
contact len care product help remov contamin surfac
contact len len rewet drop use rehydr len
wear clear away surfac materi growth daili discuss
neg impact clc market develop market
ocular allergi allerg conjunct occur conjunctiva eye
becom swollen inflamm due reaction pollen dander mold
allergy-caus substanc eye expos allergy-caus
substanc histamin releas bodi caus blood vessel
conjunctiva swell result eye becom red itchi season allerg
conjunct sac common type eye allergi allergi eye
treat variou ocular health product includ medic
antihistamin combin antihistamin red reliev
industri sale driven optometrist eye care profession recommend
well market consum awar campaign compani ocular
market along brand familiar ocular market highli competit
typic character gener competitor privat label product
compet brand product term reimburs market primarili privat
pay patient pay substanti ocular health product pocket major
ocular health product sold counter small number countri
may requir prescript
spin-off capit structur
feb novarti obtain sharehold approv spin alcon
wholly-own subsidiari novarti spun alc sharehold bil
bil stock term spin-off novarti sharehold receiv
alc share everi novarti shares/adr held prior spin-off alc
expect pay novarti bil cash relat inter-company indebted
fund proce bil debt
figur capit indebted
detail mil actualproformacash cash total net financi liabil current non-curr debt- total share capital- reserves- net parent total total ratiosnet charl martineau pm univers toronto
michael ball chairman mr ball chairman alcon board previous
ceo alcon divis serv member novarti execut committe
februari june previous serv ceo hospira inc
held number senior leadership posit
allergan inc includ presid
david endicott ceo mr endicott appoint ceo join novarti
alcon divis juli presid commerci innov chief oper
offic prior presid hospira infus system join
hospira mr endicott serv offic execut committe member allergan
timothi stonesif cfo mr stonesif appoint cfo recent
serv execut vice presid cfo hewlett packard enterpris
novemb septemb prior mr stonesif act senior
vice presid cfo enterpris group co februari novemb
join serv cfo gener motor intern oper
may januari previous serv cfo alegco scotsman june
may cfo sabic innov plastic formerli ge plastic
august june
michael onuscheck presid global busi innov mr onuscheck
appoint presid global busi innov prior
presid global busi innov alcon divis mr onuscheck join
alcon divis januari presid gener manag global
surgic franchis prior join alcon divis mr onuscheck recent held
posit presid boston scientif overse compani busi
oper europ russia also serv senior vice presid presid
neuromodul divis
jeannett bank presid gm global surgic franchis ms bank
appoint presid gm global surgic franchis prior current
role ms bank held variou manag posit merck
andi pawson presid gm global vision franchis mr pawson
appoint presid gm global vision franchis prior current
role mr pawson held variou manag posit unilev
alc current price emb expect long term sale growth assum
flat annual margin improv
ran market impli scenario use forecast holt dcf use
forecast assum annual margin improv
solv sale compound-annual-growth-rate requir justifi current price alc
sensit tabl help quantifi impact increment margin growth
alc valuat sensit top-lin growth everi increment ad
per share vs per share ad increment margin
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag inform see novemb
financi statement project
inc net interest inc high teensnet dilut adj dilut interest exp inc mid charl martineau pm univers toronto
cc cc msd cc charl martineau pm univers toronto figur alc balanc sheet
 short-term current current intang non-curr current current long-term non-curr contribut comp inc stockhold liabil sheet payabl debt debt charl martineau pm univers toronto figur alc statement
flowsnet non-cash work asset oper flowscapit use debt issu stock issuanc common fx chang time convers convers msd charl martineau pm univers toronto
compani mention price
matt miksic vik chopra christoph gretler certifi respect compani secur individu analyz view
express report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
